Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-87189401 and JNJ-78278343 in Advanced Prostate Cancer
NCT06095089Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of JNJ-87189401 and pasritamig in prostate cancer (PCa) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days and Adverse Events. Started Nov 2023; status: recruiting.
02
Drugs
JNJ-87189401pasritamig
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06095089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095089.